Daratumumab resistance is frequent in advanced‐stage multiple myeloma patients irrespective of<scp>CD</scp>38 expression and is related to dismal prognosis

Abstract

Responses to daratumumab and combinations in patients with advanced MM, particularly with extramedullary disease, are low and short-lived, stressing the administration of this agent should be early in the course of the disease.